ArticleGlobal health action2021
Expected years lived with intimate partner violence: a new approach for public health.
Article in Global health action, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Intimate Partner Violence, COVID-19 Stressors, and Intersectionality During the Perinatal Period: Dissecting the Perfect Storm.Women's health reports (New Rochelle, N.Y.) · 2025Article
- Saliva as a diagnostic tool to measure polycyclic aromatic hydrocarbon exposure in dental patients exposed to intimate partner violence (IPV).Biomedical journal · 2023Article
- Women as a driver to address gaps in the global surgical workforce.Human resources for health · 2023Article
- Self-reported history of physical intimate partner violence and longitudinal cognitive performance in midlife women.Women's health (London, England)Article
- The prevalence, incidence, and recurrence of intimate partner violence and its association with adverse childhood experiences among pregnant and breastfeeding women living with HIV in Malawi.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntimate Partner Violence against women (IPV) is a major public health problem. However, mainstream indicators used in public health are not designed to fully capture the pervasive and enduring impact of IPV.
objectiveWe propose a new indicator that considers the burden of IPV in women during their middle life years, estimating the number of years that women are expected to live under IPV, and provide estimates for 151 countries.
methodsPrevalence rates of physical and sexual IPV for a given year are taken from the Global Database on the Prevalence of Violence Against Women. Annual period life tables are constructed using data from the World Population Prospects. We use Sullivan's method to estimate partial life expectancy between the ages of 15 and 49 lived suffering from physical and sexual IPV in each country. The final indicator measures the number of years 15 to 49-year-old women are expected to live with IPV (YLIPV) in a given year.
resultsBased on data from surveys representative of 92.0% of the global female population aged between 15 to 49, we find that ever-partnered women aged between 15 to 49 are expected to live 4.1 years (Low Bound: 2.3; Upper Bound: 7.1) suffering from violence during this age range. By regions, women are expected to suffer from IPV during 6.0 years (3.7-9.2) in Africa; 4.3 years (2.4-7.8) in Asia; 3.4 years (2.1-5.6) in Oceania; 2.6 years (1.5-4.2) in the Americas; and 1.7 years (0.9-3.1) in Europe.
conclusionsYLIPV is a useful indicator to display the burden of IPV. Similarly to the mainstream public health indicators rationale, YLIPV accounts for the time women are exposed to IPV during their lifespan and it is standardized by age exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.